Home
Products
Company Info
Contact Info
Webcasts
Search

2nd Quarter Earnings LIVE
Thursday Aug 11th. 2005
10:30 a.m. ET

"Click Here"

 

News Releases

1. CORRECTION FROM SOURCE: Stellar Pharmaceuticals' Q3-2009 Financial Results Marked by Strong Growth and Continued Profitability (NOV 10, 2009)

2. Stellar Pharmaceuticals' Q3-2009 Financial Results Marked by Strong Growth and Continued Profitability (NOV 6, 2009)

3. Stellar Pharmaceuticals Signs Licensing Agreement for Distribution And Sale of Uracyst(R) in South Korea (OCT 26, 2009)

4. Stellar Pharmaceuticals' Uracyst(R) the Subject of Positive Presentation at Major Urology Conference (OCT 15, 2009)

5. Stellar Pharmaceuticals Retains Kilmer Lucas for Investor Communications (SEP 1, 2009)

6. Stellar Pharmaceuticals Announces Record Second Quarter Revenues and Profitability for the First Half (AUG 5, 2009)

7. Stellar Pharmaceuticals to Host Second Quarter 2009 Earnings Conference Call (AUG 4, 2009)

8. Stellar Pharmaceuticals Provides Guidance for 2009 Second Quarter Revenues in Excess of One Million Dollars (CDN) (JUN 19, 2009)

9. Stellar Pharmaceuticals Announces the Launch of Neovisc(R) Single Dose (JUN 18, 2009)

10. Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received a Conditional IDE Approval for Stellar's Uracyst(R) From the FDA (JUN 10, 2009)

11. Stellar Pharmaceuticals Announces Record First Quarter Financial Results and Profitability (JUN 4, 2009)

12. Stellar Pharmaceuticals Announces a Late Filing of First Quarter Financial Results Due to Change in Auditors (MAY 20, 2009)

13. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Italy (MAY 5, 2009)

14. Stellar Pharmaceuticals Inc. Announces Mr. Martin Thrasher has Joined Their Board of Directors (APR 22, 2009)

15. Stellar Pharmaceuticals Cash Positive for 2008 (APR 13, 2009)

16. Stellar Pharmaceuticals Inc. Announces Normal Course Issuer Bid (APR 9, 2009)

17. Stellar Pharmaceuticals to Present at 2009 Equities Conference and Provides International Uracyst(R) Sales Update (FEB 9, 2009)

18. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Netherlands, Belgium and Luxemburg (JAN 8, 2009)

19. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Sweden, Denmark, Finland, Norway and Iceland (DEC 10, 2008)

20. Stellar Pharmaceuticals Inc. Signs Licensing Agreement For Distribution and Sale of Uracyst(R) in United Kingdom and Ireland (DEC 9, 2008)

21. Stellar Pharmaceuticals Inc. Announces Product Revenue Increases for Both Domestic and International Markets (NOV 13, 2008)

22. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Turkey (OCT 24, 2008)

23. Stellar Pharmaceuticals Inc. Announces Successful Completion of Watson's Pilot Clinical Study (AUG 18, 2008)

24. Stellar Pharmaceuticals Inc. Announces Revenues Increased by 20.7% Gross Profits Up By 29.2% (AUG 12, 2008)

25. Stellar Pharmaceuticals Inc. Announces its Decision to Voluntary Delist From TSX Venture Exchange (JUN 9, 2008)

26. Stellar Pharmaceuticals Inc. Announces Revenue Increased by 25.7% Gross Profits up by 50.9% (MAY 15, 2008)

27. Stellar Pharmaceuticals Inc. Provides Update on Normal Course Issuer Bid & Provides Company Updates (MAY 12, 2008)

28. CORRECTION FROM SOURCE: Stellar Pharmaceuticals Inc. Announces Stock Buyback Program (APR 7, 2008)

29. Stellar Pharmaceuticals Inc. Announces Stock Buyback Program (APR 7, 2008)

30. Stellar Pharmaceuticals Announces Profitability for 2007 Fourth Quarter (MAR 31, 2008)

31. Stellar Pharmaceuticals Inc. Announces the Receipt Of Their First Order for Neovisc(R) Going to Torrex Chiesi Pharma GmbH (MAR 18, 2008)

32. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of NeoVisc(R) in Eastern Europe (NOV 14, 2007)

33. Stellar Pharmaceuticals Announces Profitability for 2007 Third Quarter Financial Results (NOV 8, 2007)

34. Stellar Pharmaceuticals Provides Strong 3rd Quarter Guidance (OCT 4, 2007)

35. Stellar Pharmaceuticals Reports the Purchase of Stellar Shares in the Open Market by CEO and CFO (SEP 25, 2007)

36. Stellar Pharmaceuticals Agrees to Settle Dispute with European Uracyst Licensee (SEP 11, 2007)

37. Stellar Pharmaceuticals Announces 2007 Second Quarter Financial Results and Uracyst(R) Updates (AUG 15, 2007)

38. Stellar Pharmaceuticals Schedules Second Quarter 2007 Financial Results and Conference Call (AUG 14, 2007)

39. Stellar Pharmaceuticals Inc. Holds Annual Shareholder Meeting (JUN 22, 2007)

40. Stellar Pharmaceuticals Retains Investment Banking Firm Ladenburg Thalmann (JUN 7, 2007)

41. Stellar Pharmaceuticals Announces 2007 First Quarter Financial Results (MAY 11, 2007)

42. Stellar Pharmaceuticals Schedules First Quarter 2007 Financial Results and Conference Call (MAY 8, 2007)

43. CORRECTION FROM SOURCE: Stellar Pharmaceuticals Announces 2006 Fourth Quarter and Year-End Financial Results (MAR 30, 2007)

44. Stellar Pharmaceuticals Announces 2006 Fourth Quarter and Year-End Financial Results (MAR 30, 2007)

45. Stellar Pharmaceuticals Schedules Fourth Quarter and Year End Financial Results and Conference Call (MAR 28, 2007)

46. Stellar Pharmaceuticals Announces John Gregory Founder of King Pharma and Stellar's Largest Shareholder Has Joined the Board of Directors (FEB 26, 2007)

47. Stellar Pharmaceuticals Retains Investor Relations Firm (DEC 27, 2006)

48. Stellar Pharmaceuticals Achieves Profitability for 2006 (DEC 22, 2006)

49. Stellar Pharmaceuticals Signs License and Supply Agreements With Watson Pharmaceuticals for Stellar's Uracyst'R' Product (DEC 14, 2006)

50. Stellar Pharmaceuticals Announces 2006 Third Quarter Financial Results (NOV 9, 2006)

51. Stellar Pharmaceuticals Schedules Third Quarter Financial Results and Conference Call (NOV 2, 2006)

52. Stellar Pharmaceuticals Receives CE Mark For NeoVisc'R' (AUG 30, 2006)

53. Stellar Pharmaceuticals Announces 2006 Second Quarter Financial Results (AUG 10, 2006)

54. Stellar Pharmaceuticals Schedules Second Quarter Financial Results and Conference Call (AUG 9, 2006)

55. Stellar Pharmaceuticals & Bio-Technic Sign Licensing Agreement for Neovisc'R' in Romania (JUL 13, 2006)

56. Stellar Pharmaceuticals Announces 2006 First Quarter Financial Results (MAY 11, 2006)

57. Stellar Pharmaceuticals Schedules First Quarter Financial Results and Conference Call (MAY 8, 2006)

58. Stellar Pharmaceuticals Announces Presentation of NMP22'R' BladderChek'R' Test at The 21st Annual Congress of The European Association of Urology (APR 10, 2006)

59. Stellar Pharmaceuticals Announces 2005 Fourth Quarter and Year End Financial Results (MAR 31, 2006)

60. Stellar Pharmaceuticals Reschedules Fourth Quarter and Year End Financial Results and Conference Call (MAR 28, 2006)

61. Stellar Pharmaceuticals Announces the Successful Completion of a Quality Management System Upgrade (MAR 23, 2006)

62. Stellar Pharmaceuticals Schedules Fourth Quarter and Year End Financial Results and Conference Call (MAR 22, 2006)

63. Stellar Pharmaceuticals to Present at Brean Murray, Carret & Co. Small Cap Institutional Investor Conference (JAN 25, 2006)

64. Stellar Pharmaceuticals and Al-Mohab Trading & Contracting Company Sign Licensing Agreement for NeoVisc'R' in Kuwait (JAN 10, 2006)

65. CORRECTION FROM SOURCE: Stellar Pharmaceuticals Inc. Reports Grant Of Options To Officers And Directors (DEC 22, 2005)

66. Stellar Pharmaceuticals Inc. Reports Grant Of Options To Officers And Directors (DEC 22, 2005)

67. Stellar Pharmaceuticals and Megapharm Sign Licensing Agreement for Uracyst'R' in Israel (DEC 20, 2005)

68. Stellar Re-files Annual and Interim CEO and CFO Certifications (NOV 11, 2005)

69. Stellar Pharmaceuticals Reports Third Quarter Financial Results (NOV 10, 2005)

70. Stellar Pharmaceuticals Schedules Third Quarter Financial Results And Conference Call (NOV 7, 2005)

71. Stellar Pharmaceuticals Named to 2005 Deloitte Technology Fast 500 List (OCT 21, 2005)

72. Stellar Pharmaceuticals Launches a Higher Molecular Weight Hyaluronate Formulation for NeoVisc'R' (OCT 13, 2005)

73. CORRECTION FROM SOURCE: Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Uracyst'R' In China (SEP 29, 2005)

74. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Uracyst'R' In China (SEP 29, 2005)

75. Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of NeoVisc'R' in Lebanon and Syria (AUG 22, 2005)

76. Stellar Pharmaceuticals Inc. Retains Basic Investors, Inc. (AUG 12, 2005)

77. Stellar Pharmaceuticals Announces 2005 Second Quarter Financial Results (AUG 11, 2005)

78. Stellar Pharmaceuticals Schedules Second Quarter Financial Results and Conference Call (AUG 8, 2005)

79. Stellar Pharmaceuticals Inc. Names Patrick Scrivens as Advisor (JUL 15, 2005)

80. Stellar Pharmaceuticals Inc. and InnoGen Ltd. Sign NeoVisc'R' Licensing Agreement for Turkey (JUL 14, 2005)

81. CORRECTION FROM SOURCE: Stellar Pharmaceuticals Inc. Nominates Medical Device Industry Veteran Robert H. Kayser for Election to Board of Directors (JUN 8, 2005)

82. Stellar Pharmaceuticals Inc. Nominates Medical Device Industry Veteran Robert H. Kayser for Election to Board of Directors (JUN 7, 2005)

83. Stellar Pharmaceuticals Inc. Reports Grant of Options to Officers and Directors (MAY 13, 2005)

84. Stellar Pharmaceuticals Inc. Announces 2005 First Quarter Financial Results (MAY 11, 2005)

85. Stellar Pharmaceuticals Schedules First Quarter Financial Results And Conference Call (MAY 9, 2005)

86. Stellar Pharmaceuticals Inc. Announces Launch of Uracyst in the United Kingdom (MAY 9, 2005)

87. Stellar Pharmaceuticals Announces 2004 Financial Results (MAR 31, 2005)

88. Stellar Pharmaceuticals Schedules Fourth Quarter And Year-End Financial Results And Conference Call (MAR 29, 2005)

89. Stellar Pharmaceuticals Inc.: Journal of the American Medical Association Reports NMP22 BladderChek Test Detects Bladder Cancers Missed by Cystoscopy (FEB 22, 2005)

90. Stellar Pharmaceuticals Inc. Appoints Investor Relations Firms (JAN 7, 2005)

91. Stellar International Inc. Changes Name to Stellar Pharmaceuticals Inc. (JAN 4, 2005)

92. Stellar International Inc. Reports Grant of Options to Investor Relations Firms (DEC 3, 2004)

93. CORRECTION FROM SOURCE: Stellar International Reports Continued Revenue Growth for Third Quarter and Nine Months (NOV 15, 2004)

94. Stellar International Reports Continued Revenue Growth for Third Quarter and Nine Months (NOV 15, 2004)

95. Stellar International Announces Date of its 3Q'04 Results Release and Conference Call (NOV 10, 2004)

96. Stellar International Inc. Launches Sales Of NMP22'R' BladderChek'R' In Canada (NOV 1, 2004)

97. Stellar International To Present At Healthpoint Capital's Biomaterials Summit In New York (OCT 8, 2004)

98. Statement By Stellar International Inc. (OCT 7, 2004)

99. Stellar International Inc. Receives Approval From Health Canada to Market NMP22'R' BladderChek'R' for the Diagnosis and Monitoring of Bladder Cancer (SEP 20, 2004)

100. Stellar International Inc. and Tripti Bumis Sdn. Bhd. Sign Neovisc'R' Licensing Agreement for Malaysia, Singapore and Brunei (SEP 9, 2004)

101. Stellar International Inc Enters into Licensing Agreement with Pharmore GmbH for NeoVisc 'R' in Germany (AUG 18, 2004)

102. Stellar International Reports Second Quarter Results (AUG 16, 2004)

103. Stellar International Announces Date Of Its Second-Quarter 2004 Results Release And Conference Call (AUG 9, 2004)

104. Stellar International Broadens its Distribution Network for NeoVisc'R' (AUG 9, 2004)

105. Stellar International Inc. Appoints Arnold S. Tenney As Chairman Of The Board (JUL 15, 2004)

106. Statement by Stellar International (JUL 15, 2004)

107. Stellar International Inc. Expanding From Medical Devices To Pharmaceutical Products (JUN 24, 2004)

108. Stellar International Inc Moves Its Manufacturing To Dalton Chemicals Laboratories Inc (MAY 25, 2004)

109. Stellar International Announces First Quarter 2004 Results; Revenue and Margins Climb, Loss Drops (US DOLLARS/USGAAP) (MAY 19, 2004)

110. Stellar International Announces Date Of Its First Quarter 2004 Results Release And Conference Call (MAY 13, 2004)

111. Stellar International Inc. Selects Allen & Caron for Corporate Communications, Investor and Media Relations (APR 22, 2004)

112. CORRECTION FROM SOURCE: Stellar International Inc. Reports Revenue Growth Of 29.8% For The Year Ended December 31, 2003 (APR 14, 2004)

113. Stellar International Inc. Reports Revenue Growth Of 29.8% For The Year Ended December 31, 2003 (APR 13, 2004)

114. Stellar International Inc. Reports Grant of Options to Directors (APR 2, 2004)

115. Stellar International Inc. Signs Supply and Out-License Agreements for NeoVisc(R) and Uracyst(R) with SJ Pharmaceuticals Inc. for the United States Market. (MAR 25, 2004)

116. Stellar International Participates in Broadcast Interviews with CEOCast and the Wall Street Reporter (MAR 1, 2004)

117. Stellar International Inc. and SJ Strategic Investments LLC Announce Private Placement of Over 4 Million Common Shares of Stellar to SJ (FEB 19, 2004)

118. Stellar International Inc. Launches Skelite In Canada (JAN 29, 2004)

119. Stellar Retains Consultant (JAN 21, 2004)

120. Stellar International Inc. Moves to Tier 2 of the TSX Venture Exchange and Receives New Trading Symbol (JAN 6, 2004)

121. Stellar International Receives Second Milestone Payment for the European Market (DEC 22, 2003)

122. Stellar International's Uracyst(R)-S is Launched in Europe (DEC 1, 2003)

123. Stellar Announces Grant of Options (NOV 19, 2003)

124. Stellar International Reports Continued Revenue Growth For Third Quarter And Nine Months (NOV 17, 2003)

125. Stellar International Inc. Announces First Licensing Agreement (JAN 11, 2002)

126. Stellar International Reports Second Quarter & First Half Revenue Gains (JUL 26, 2001)

127. Stellar International Inc. Reports First Quarter Revenue and Gross Profit Increases (JUN 7, 2001)

128. Stellar International Inc. - Announcement (DEC 5, 2000)